Lot Of Inversion Talk, But Do You Know The Basics?
Much ink has been spilt recently on the topic of "inversion" transactions — from Pfizer's failed pursuit of AstraZeneca, to the $48 billion Medtronic/Covidien deal, to the more recent and creative...To view the full article, register now.
Already a subscriber? Click here to view full article